A commentary on pharmacogenomics: What can it do?

The article presents information on pharmacogenomics. What pharmacogenomics means is a legitimate concern about which members of the pharmaceutical industry and the healthcare market should be aware and be willing to take time to explain. Regulators from Capitol Hill to local communities can have a dramatic impact upon the emerging field of pharmacogenomics. The U.S. Food and Drug Administration adopted an opinion on pharmacogenomic testing as it relates to new drug approval and published this landmark document in November 2003.